The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing ...

Most drug development focuses on tweaking molecules to improve their ability to slip through cell ... large-sized drugs known as bRo5 molecules, such as PROTACs, a type of targeted cancer therapy ...

Rule-breaking drug design takes advantage of CD36-dependent pathway A research team of scientists from Duke University School ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Hui-Kuan Lin, PhD, study author, cancer ... of Pathology, Duke University School of Medicine Most drug development focuses on tweaking molecules to improve their ability to slip through cell ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium ...

Artificial intelligence models, pretrained on vast datasets, significantly outperformed a standard baseline model in ...

Scientists could reshape cancer ... of Pathology at Duke University School of Medicine. Most drug development focuses on tweaking molecules to improve their ability to slip through cell membranes ...

a cancer biology researcher and professor in the Department of Pathology at Duke University School of Medicine. Most drug development focuses on tweaking molecules to improve their ability to slip ...

Ahead of this year’s meeting of the American Association for Cancer Research (AACR), the ... to the molecular classification of diffuse large B-cell lymphoma, including the identification ...